3 citations
,
April 2016 in “Research and reports in urology” The new saw palmetto extract effectively inhibits an enzyme linked to prostate enlargement and may be as good as standard treatments.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
March 2025 in “Journal of Investigative Dermatology” January 2002 in “Dialnet (Universidad de la Rioja)” Finasteride treatment makes the prostate look more like a healthy one.
August 2026 in “Canadian Journal of Health Technologies” Litfulo is recommended for treating severe alopecia areata in people 12 and older, as it helps hair regrowth.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
2 citations
,
April 2016 in “DOAJ (DOAJ: Directory of Open Access Journals)” The saw palmetto extract effectively inhibits an enzyme linked to prostate issues, showing promise for prostate health.
September 2025 in “Value in Health”
1 citations
,
November 2023 in “Indian Journal of Science and Technology” Eclipta alba may improve memory and help treat Alzheimer's disease.
1 citations
,
September 2025 in “Archivio Italiano di Urologia e Andrologia” Serenoa repens extract, alone or with other supplements, improves urinary symptoms and lowers PSA levels.
11 citations
,
November 2011 in “Neuroreport” Paroxetine relieves pain by increasing allopregnanolone levels.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”
6 citations
,
August 2017 in “Physiological Research” Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
June 2026 in “Journal of cancer research updates” Generic Palbociclib is safe and tolerable for treating certain breast cancer types.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
1 citations
,
June 2026 in “Dermato” Ritlecitinib is effective for treating alopecia areata, showing significant hair regrowth with mild side effects.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
June 2026 in “British Journal of Dermatology” Ritlecitinib is effective and safe for treating alopecia areata, especially in newer cases.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
July 2026 in “Journal of the American Academy of Dermatology” 49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
1 citations
,
January 2023 in “Bioscience Journal” Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
Marine sponges from Tabuhan Island can inhibit enzymes linked to Alzheimer's and hair loss.
March 2026 in “Tropical Journal of Natural Product Research” Albizia saponaria bark extract may help treat hair loss.
8 citations
,
March 2019 in “Drugs - Real World Outcomes” Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.